Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic version of Spiriva (Tiotropium bromide).

Lutio has been approved for the treatment of chronic obstructive pulmonary disease (COPD).

It is the second inhalation product for the British market from Lupin Healthcare after Luforbec pressurized metered dose inhaler (pMDI).

Thierry Volle — Lupin EMEA President said: “We are pleased to have received the approval of Lutio from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in UK.”

Tiotropium is utilized for alleviating wheezing, coughing, shortness of breath, and tightness in the chest in patients having COPD.

  chronic obstructive pulmonary disease, COPD, cough, Luforbec, Lupin, Lupin Healthcare (UK), Spiriva, Thierry Volle, Tiotropium Bromide, UK Medicines and Healthcare Products Regulatory Agency, United Kingdom